Bioverativ (NASDAQ: BIVV) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Bioverativ to related businesses based on the strength of its earnings, valuation, dividends, institutional ownership, analyst recommendations, risk and profitability.
Earnings and Valuation
This table compares Bioverativ and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Bioverativ||$887.40 million||$439.60 million||N/A|
|Bioverativ Competitors||$284.28 million||$34.29 million||135.04|
Insider & Institutional Ownership
95.2% of Bioverativ shares are held by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a summary of current recommendations for Bioverativ and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Bioverativ presently has a consensus price target of $60.36, suggesting a potential upside of 19.09%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 47.13%. Given Bioverativ’s peers stronger consensus rating and higher probable upside, analysts clearly believe Bioverativ has less favorable growth aspects than its peers.
This table compares Bioverativ and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Bioverativ beats its peers on 7 of the 11 factors compared.
Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person’s blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).
What are top analysts saying about Bioverativ Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bioverativ Inc and related companies.